Preliminary MAGMAP trial results in 62 patients show a 96% sentinel node identification rate and no false negatives in the ...
Next-generation anti-IgE monoclonal antibody becomes the first biologic candidate in China to file a BLA for seasonal ...
Blood-brain barrier-penetrating therapy targets MPS IIIB, an ultra-rare lysosomal storage disorder with no currently approved ...
The FACSDiscover A7 Cell Analyzer sets a new standard for experimental standardization in flow cytometry Waters Corporation ...
Icosagen, a private European protein therapeutics CRDMO, and EPOK Therapeutics Inc., a pre-clinical-stage biopharmaceutical ...
New stackable chambers provide precise environmental control, remote monitoring and data logging for pharmaceutical, biotech, ...
Combination brings single-cell and spatial transcriptomics together with GLP/GCLP-compliant qPCR and bioanalytical ...
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet ...
Twenty-six figures, each cited to a primary disclosure with its date attached, that together tell the Asia-Pacific biopharma year: where the capital concentrated, what the deals validated, how a ...
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first viral vector Contract Development and Manufacturing Organisation (CDMO) advises that the Therapeutic Goods Administration (TGA) ...
Accro Bioscience announced tha t AC-101 tablets have been included in the Rare Diseases Innovative Drug Development ...
Korea's health ministry estimates that between 10,000 and 20,000 of its citizens travel abroad every year for stem cell treatment. Fourteen months after the country legalised a domestic route, exactly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results